Seeking Alpha

Johns Hopkins doctor challenges approval of AZN's Brilinta

  • An adjunct medical professor at Johns Hopkins Hospital has challenged the FDA's 2011 approval of AstraZeneca's anticlotting drug Brilinta, the WSJ reports.
  • Using the federal False Claims Act, Victor Serebruany has filed a complaint arguing that data was manipulated in a trial which showed that the medicine saved lives and cut heart attacks. The U.S. attorney's office in Washington DC is investigating the conduct of the trial.
  • Separately, AstraZeneca (AZN) has completed the acquisition of Bristol-Myers Squibb's (BMY) holding in the companies' diabetes joint venture for an initial $2.7B and as much as $1.65B in additional payments, as well as royalties on sales. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|